• All News
• Consumer
• Pro
• New Drugs
• Pipeline
• Clinical Trials
• FDA Alerts

GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 30, 2025.

By Lori Solomon HealthDay Reporter

THURSDAY, Jan. 30, 2025 -- The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a study published online Jan. 23 in JAMA Otolaryngology-Head & Neck Surgery.

Juan P. Brito, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues estimated the risk for incident thyroid cancer among adults with type 2 diabetes being treated with GLP-1 RAs versus other common glucose-lowering medications. The analysis included 41,112 patients starting treatment with GLP-1 RAs; 76,093 starting a dipeptidyl peptidase-4 inhibitor (DPP4i); 43,499 starting a sodium-glucose cotransporter 2 inhibitor (SGLT2i); and 191,209 starting sulfonylurea therapy.

The researchers found that the numbers of patients diagnosed with thyroid cancer were 0.17 percent in the GLP-1 RA group, 0.23 percent in the DPP4i group, 0.17 percent in the SGLT2i group, and 0.20 percent in the sulfonylurea group. GLP-1 RA initiation was not significantly associated with an increased overall risk for thyroid cancer versus the other diabetes drugs in the modified intention-to-treat analysis (hazard ratio [HR], 1.24; 95 percent confidence interval [CI], 0.88 to 1.76). In the first year after GLP-1 RA initiation, thyroid cancer risk was elevated (HR, 1.85; 95 percent CI, 1.11 to 3.08) and was amplified in the overall as-treated analysis that restricted patients from analysis when therapy was discontinued or another medication was added (HR, 2.07; 95 percent CI, 1.10 to 3.95).

"These findings indicate that GLP-1 RA initiation was associated with new diagnosis of thyroid cancer only in the short term, likely due to increased vigilance and case detection rather than de novo pathogenesis," the authors write.

Several authors disclosed ties to relevant organizations.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted January 2025

More news resources

• FDA Medwatch Drug Alerts
• Daily MedNews
• News for Health Professionals
• New Drug Approvals
• New Drug Applications
• Drug Shortages
• Clinical Trial Results
• Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.